世界の急性リンパ芽球性白血病（ALL）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Acute Lymphoblastic Leukemia Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0066 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、127ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、急性リンパ芽球性白血病（ALL）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、標的療法、放射線療法、幹細胞移植）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・急性リンパ芽球性白血病（ALL）治療の市場動向 ・企業の競争状況、市場シェア ・急性リンパ芽球性白血病（ALL）治療の種類別市場規模（化学療法、標的療法、放射線療法、幹細胞移植） ・急性リンパ芽球性白血病（ALL）治療の用途別市場規模（病院、薬局） ・急性リンパ芽球性白血病（ALL）治療の北米市場規模2016-2027（アメリカ、カナダ） ・急性リンパ芽球性白血病（ALL）治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・急性リンパ芽球性白血病（ALL）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・急性リンパ芽球性白血病（ALL）治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・急性リンパ芽球性白血病（ALL）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Erytech Pharma、Spectrum Pharmaceuticals、Pfizer、Sigma-Tau、Takeda、Genzyme Corporatio、GSK、Amgen、EUSA Pharma、ARIAD Pharmaceuticals、Talon Therapeutics、Enzon, Inc.、Nova Laboratories、Bristol-Myers Squibb、Silvergate Pharmaceuticals） ・結論

Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes.

Market Analysis and Insights: Global Acute Lymphoblastic Leukemia Therapeutics Market
The global Acute Lymphoblastic Leukemia Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Acute Lymphoblastic Leukemia Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Acute Lymphoblastic Leukemia Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Acute Lymphoblastic Leukemia Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Acute Lymphoblastic Leukemia Therapeutics market.

Global Acute Lymphoblastic Leukemia Therapeutics Scope and Market Size
Acute Lymphoblastic Leukemia Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Acute Lymphoblastic Leukemia Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Chemotherapy
Targeted Therapy
Radiation Therapy
Stem cell Transplantation

Segment by Application
Hospital
Pharmacy

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Erytech Pharma
Spectrum Pharmaceuticals
Pfizer
Sigma-Tau
Takeda
Genzyme Corporatio
GSK
Amgen
EUSA Pharma
Sigma-Tau
Takeda
Enzon, Inc.
Nova Laboratories

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Lymphoblastic Leukemia Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Radiation Therapy
1.2.5 Stem cell Transplantation
1.3 Market by Application
1.3.1 Global Acute Lymphoblastic Leukemia Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Acute Lymphoblastic Leukemia Therapeutics Market Perspective (2016-2027)
2.2 Acute Lymphoblastic Leukemia Therapeutics Growth Trends by Regions
2.2.1 Acute Lymphoblastic Leukemia Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Acute Lymphoblastic Leukemia Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Acute Lymphoblastic Leukemia Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Acute Lymphoblastic Leukemia Therapeutics Industry Dynamic
2.3.1 Acute Lymphoblastic Leukemia Therapeutics Market Trends
2.3.2 Acute Lymphoblastic Leukemia Therapeutics Market Drivers
2.3.3 Acute Lymphoblastic Leukemia Therapeutics Market Challenges
2.3.4 Acute Lymphoblastic Leukemia Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Acute Lymphoblastic Leukemia Therapeutics Players by Revenue
3.1.1 Global Top Acute Lymphoblastic Leukemia Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Acute Lymphoblastic Leukemia Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Acute Lymphoblastic Leukemia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Acute Lymphoblastic Leukemia Therapeutics Revenue
3.4 Global Acute Lymphoblastic Leukemia Therapeutics Market Concentration Ratio
3.4.1 Global Acute Lymphoblastic Leukemia Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Lymphoblastic Leukemia Therapeutics Revenue in 2020
3.5 Acute Lymphoblastic Leukemia Therapeutics Key Players Head office and Area Served
3.6 Key Players Acute Lymphoblastic Leukemia Therapeutics Product Solution and Service
3.7 Date of Enter into Acute Lymphoblastic Leukemia Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Acute Lymphoblastic Leukemia Therapeutics Breakdown Data by Type
4.1 Global Acute Lymphoblastic Leukemia Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Acute Lymphoblastic Leukemia Therapeutics Forecasted Market Size by Type (2022-2027)

5 Acute Lymphoblastic Leukemia Therapeutics Breakdown Data by Application
5.1 Global Acute Lymphoblastic Leukemia Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Acute Lymphoblastic Leukemia Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Acute Lymphoblastic Leukemia Therapeutics Market Size (2016-2027)
6.2 North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Type
6.2.1 North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2027)
6.3 North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Application
6.3.1 North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2027)
6.4 North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Country
6.4.1 North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Acute Lymphoblastic Leukemia Therapeutics Market Size (2016-2027)
7.2 Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Type
7.2.1 Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2027)
7.3 Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Application
7.3.1 Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2027)
7.4 Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Country
7.4.1 Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Type
8.2.1 Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Application
8.3.1 Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Region
8.4.1 Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size (2016-2027)
9.2 Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Type
9.2.1 Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Application
9.3.1 Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Country
9.4.1 Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Type
10.2.1 Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Application
10.3.1 Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Country
10.4.1 Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Erytech Pharma
11.1.1 Erytech Pharma Company Details
11.1.2 Erytech Pharma Business Overview
11.1.3 Erytech Pharma Acute Lymphoblastic Leukemia Therapeutics Introduction
11.1.4 Erytech Pharma Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.1.5 Erytech Pharma Recent Development
11.2 Spectrum Pharmaceuticals
11.2.1 Spectrum Pharmaceuticals Company Details
11.2.2 Spectrum Pharmaceuticals Business Overview
11.2.3 Spectrum Pharmaceuticals Acute Lymphoblastic Leukemia Therapeutics Introduction
11.2.4 Spectrum Pharmaceuticals Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.2.5 Spectrum Pharmaceuticals Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Acute Lymphoblastic Leukemia Therapeutics Introduction
11.3.4 Pfizer Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Sigma-Tau
11.4.1 Sigma-Tau Company Details
11.4.2 Sigma-Tau Business Overview
11.4.3 Sigma-Tau Acute Lymphoblastic Leukemia Therapeutics Introduction
11.4.4 Sigma-Tau Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.4.5 Sigma-Tau Recent Development
11.5 Takeda
11.5.1 Takeda Company Details
11.5.2 Takeda Business Overview
11.5.3 Takeda Acute Lymphoblastic Leukemia Therapeutics Introduction
11.5.4 Takeda Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.5.5 Takeda Recent Development
11.6 Genzyme Corporatio
11.6.1 Genzyme Corporatio Company Details
11.6.2 Genzyme Corporatio Business Overview
11.6.3 Genzyme Corporatio Acute Lymphoblastic Leukemia Therapeutics Introduction
11.6.4 Genzyme Corporatio Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.6.5 Genzyme Corporatio Recent Development
11.7 GSK
11.7.1 GSK Company Details
11.7.2 GSK Business Overview
11.7.3 GSK Acute Lymphoblastic Leukemia Therapeutics Introduction
11.7.4 GSK Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.7.5 GSK Recent Development
11.8 Amgen
11.8.1 Amgen Company Details
11.8.2 Amgen Business Overview
11.8.3 Amgen Acute Lymphoblastic Leukemia Therapeutics Introduction
11.8.4 Amgen Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.8.5 Amgen Recent Development
11.9 EUSA Pharma
11.9.1 EUSA Pharma Company Details
11.9.2 EUSA Pharma Business Overview
11.9.3 EUSA Pharma Acute Lymphoblastic Leukemia Therapeutics Introduction
11.9.4 EUSA Pharma Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.9.5 EUSA Pharma Recent Development
11.10 ARIAD Pharmaceuticals
11.10.1 ARIAD Pharmaceuticals Company Details
11.10.2 ARIAD Pharmaceuticals Business Overview
11.10.3 ARIAD Pharmaceuticals Acute Lymphoblastic Leukemia Therapeutics Introduction
11.10.4 ARIAD Pharmaceuticals Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.10.5 ARIAD Pharmaceuticals Recent Development
11.11 Talon Therapeutics
11.11.1 Talon Therapeutics Company Details
11.11.2 Talon Therapeutics Business Overview
11.11.3 Talon Therapeutics Acute Lymphoblastic Leukemia Therapeutics Introduction
11.11.4 Talon Therapeutics Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.11.5 Talon Therapeutics Recent Development
11.12 Enzon, Inc.
11.12.1 Enzon, Inc. Company Details
11.12.2 Enzon, Inc. Business Overview
11.12.3 Enzon, Inc. Acute Lymphoblastic Leukemia Therapeutics Introduction
11.12.4 Enzon, Inc. Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.12.5 Enzon, Inc. Recent Development
11.13 Nova Laboratories
11.13.1 Nova Laboratories Company Details
11.13.2 Nova Laboratories Business Overview
11.13.3 Nova Laboratories Acute Lymphoblastic Leukemia Therapeutics Introduction
11.13.4 Nova Laboratories Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.13.5 Nova Laboratories Recent Development
11.14 Bristol-Myers Squibb
11.14.1 Bristol-Myers Squibb Company Details
11.14.2 Bristol-Myers Squibb Business Overview
11.14.3 Bristol-Myers Squibb Acute Lymphoblastic Leukemia Therapeutics Introduction
11.14.4 Bristol-Myers Squibb Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.14.5 Bristol-Myers Squibb Recent Development
11.15 Silvergate Pharmaceuticals
11.15.1 Silvergate Pharmaceuticals Company Details
11.15.2 Silvergate Pharmaceuticals Business Overview
11.15.3 Silvergate Pharmaceuticals Acute Lymphoblastic Leukemia Therapeutics Introduction
11.15.4 Silvergate Pharmaceuticals Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
11.15.5 Silvergate Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Acute Lymphoblastic Leukemia Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Radiation Therapy
Table 5. Key Players of Stem cell Transplantation
Table 6. Global Acute Lymphoblastic Leukemia Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Acute Lymphoblastic Leukemia Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Acute Lymphoblastic Leukemia Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Acute Lymphoblastic Leukemia Therapeutics Market Share by Regions (2016-2021)
Table 10. Global Acute Lymphoblastic Leukemia Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Acute Lymphoblastic Leukemia Therapeutics Market Share by Regions (2022-2027)
Table 12. Acute Lymphoblastic Leukemia Therapeutics Market Trends
Table 13. Acute Lymphoblastic Leukemia Therapeutics Market Drivers
Table 14. Acute Lymphoblastic Leukemia Therapeutics Market Challenges
Table 15. Acute Lymphoblastic Leukemia Therapeutics Market Restraints
Table 16. Global Acute Lymphoblastic Leukemia Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Acute Lymphoblastic Leukemia Therapeutics Market Share by Players (2016-2021)
Table 18. Global Top Acute Lymphoblastic Leukemia Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acute Lymphoblastic Leukemia Therapeutics as of 2020)
Table 19. Ranking of Global Top Acute Lymphoblastic Leukemia Therapeutics Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Acute Lymphoblastic Leukemia Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Acute Lymphoblastic Leukemia Therapeutics Product Solution and Service
Table 23. Date of Enter into Acute Lymphoblastic Leukemia Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Acute Lymphoblastic Leukemia Therapeutics Revenue Market Share by Type (2016-2021)
Table 27. Global Acute Lymphoblastic Leukemia Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Acute Lymphoblastic Leukemia Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Acute Lymphoblastic Leukemia Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Acute Lymphoblastic Leukemia Therapeutics Revenue Market Share by Application (2016-2021)
Table 31. Global Acute Lymphoblastic Leukemia Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Acute Lymphoblastic Leukemia Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 63. Erytech Pharma Company Details
Table 64. Erytech Pharma Business Overview
Table 65. Erytech Pharma Acute Lymphoblastic Leukemia Therapeutics Product
Table 66. Erytech Pharma Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 67. Erytech Pharma Recent Development
Table 68. Spectrum Pharmaceuticals Company Details
Table 69. Spectrum Pharmaceuticals Business Overview
Table 70. Spectrum Pharmaceuticals Acute Lymphoblastic Leukemia Therapeutics Product
Table 71. Spectrum Pharmaceuticals Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 72. Spectrum Pharmaceuticals Recent Development
Table 73. Pfizer Company Details
Table 74. Pfizer Business Overview
Table 75. Pfizer Acute Lymphoblastic Leukemia Therapeutics Product
Table 76. Pfizer Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 77. Pfizer Recent Development
Table 78. Sigma-Tau Company Details
Table 79. Sigma-Tau Business Overview
Table 80. Sigma-Tau Acute Lymphoblastic Leukemia Therapeutics Product
Table 81. Sigma-Tau Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 82. Sigma-Tau Recent Development
Table 83. Takeda Company Details
Table 84. Takeda Business Overview
Table 85. Takeda Acute Lymphoblastic Leukemia Therapeutics Product
Table 86. Takeda Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 87. Takeda Recent Development
Table 88. Genzyme Corporatio Company Details
Table 89. Genzyme Corporatio Business Overview
Table 90. Genzyme Corporatio Acute Lymphoblastic Leukemia Therapeutics Product
Table 91. Genzyme Corporatio Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 92. Genzyme Corporatio Recent Development
Table 93. GSK Company Details
Table 94. GSK Business Overview
Table 95. GSK Acute Lymphoblastic Leukemia Therapeutics Product
Table 96. GSK Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 97. GSK Recent Development
Table 98. Amgen Company Details
Table 99. Amgen Business Overview
Table 100. Amgen Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 101. Amgen Recent Development
Table 102. EUSA Pharma Company Details
Table 103. EUSA Pharma Business Overview
Table 104. EUSA Pharma Acute Lymphoblastic Leukemia Therapeutics Product
Table 105. EUSA Pharma Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 106. EUSA Pharma Recent Development
Table 107. ARIAD Pharmaceuticals Company Details
Table 108. ARIAD Pharmaceuticals Business Overview
Table 109. ARIAD Pharmaceuticals Acute Lymphoblastic Leukemia Therapeutics Product
Table 110. ARIAD Pharmaceuticals Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 111. ARIAD Pharmaceuticals Recent Development
Table 112. Talon Therapeutics Company Details
Table 113. Talon Therapeutics Business Overview
Table 114. Talon Therapeutics Acute Lymphoblastic Leukemia Therapeutics Product
Table 115. Talon Therapeutics Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 116. Talon Therapeutics Recent Development
Table 117. Enzon, Inc. Company Details
Table 118. Enzon, Inc. Business Overview
Table 119. Enzon, Inc. Acute Lymphoblastic Leukemia Therapeutics Product
Table 120. Enzon, Inc. Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 121. Enzon, Inc. Recent Development
Table 122. Nova Laboratories Company Details
Table 123. Nova Laboratories Business Overview
Table 124. Nova Laboratories Acute Lymphoblastic Leukemia Therapeutics Product
Table 125. Nova Laboratories Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 126. Nova Laboratories Recent Development
Table 127. Bristol-Myers Squibb Company Details
Table 128. Bristol-Myers Squibb Business Overview
Table 129. Bristol-Myers Squibb Acute Lymphoblastic Leukemia Therapeutics Product
Table 130. Bristol-Myers Squibb Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 131. Bristol-Myers Squibb Recent Development
Table 132. Silvergate Pharmaceuticals Company Details
Table 133. Silvergate Pharmaceuticals Business Overview
Table 134. Silvergate Pharmaceuticals Acute Lymphoblastic Leukemia Therapeutics Product
Table 135. Silvergate Pharmaceuticals Revenue in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021) & (US$ Million)
Table 136. Silvergate Pharmaceuticals Recent Development
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Acute Lymphoblastic Leukemia Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Chemotherapy Features
Figure 3. Targeted Therapy Features
Figure 4. Radiation Therapy Features
Figure 5. Stem cell Transplantation Features
Figure 6. Global Acute Lymphoblastic Leukemia Therapeutics Market Share by Application: 2020 VS 2027
Figure 7. Hospital Case Studies
Figure 8. Pharmacy Case Studies
Figure 9. Acute Lymphoblastic Leukemia Therapeutics Report Years Considered
Figure 10. Global Acute Lymphoblastic Leukemia Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Acute Lymphoblastic Leukemia Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Acute Lymphoblastic Leukemia Therapeutics Market Share by Regions: 2020 VS 2027
Figure 13. Global Acute Lymphoblastic Leukemia Therapeutics Market Share by Regions (2022-2027)
Figure 14. Global Acute Lymphoblastic Leukemia Therapeutics Market Share by Players in 2020
Figure 15. Global Top Acute Lymphoblastic Leukemia Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acute Lymphoblastic Leukemia Therapeutics as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Acute Lymphoblastic Leukemia Therapeutics Revenue in 2020
Figure 17. Global Acute Lymphoblastic Leukemia Therapeutics Revenue Market Share by Type (2016-2021)
Figure 18. Global Acute Lymphoblastic Leukemia Therapeutics Revenue Market Share by Type (2022-2027)
Figure 19. North America Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Acute Lymphoblastic Leukemia Therapeutics Market Share by Type (2016-2027)
Figure 21. North America Acute Lymphoblastic Leukemia Therapeutics Market Share by Application (2016-2027)
Figure 22. North America Acute Lymphoblastic Leukemia Therapeutics Market Share by Country (2016-2027)
Figure 23. United States Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Acute Lymphoblastic Leukemia Therapeutics Market Share by Type (2016-2027)
Figure 27. Europe Acute Lymphoblastic Leukemia Therapeutics Market Share by Application (2016-2027)
Figure 28. Europe Acute Lymphoblastic Leukemia Therapeutics Market Share by Country (2016-2027)
Figure 29. Germany Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market Share by Region (2016-2027)
Figure 39. China Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Acute Lymphoblastic Leukemia Therapeutics Market Share by Type (2016-2027)
Figure 47. Latin America Acute Lymphoblastic Leukemia Therapeutics Market Share by Application (2016-2027)
Figure 48. Latin America Acute Lymphoblastic Leukemia Therapeutics Market Share by Country (2016-2027)
Figure 49. Mexico Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Acute Lymphoblastic Leukemia Therapeutics Market Share by Country (2016-2027)
Figure 55. Turkey Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Acute Lymphoblastic Leukemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Erytech Pharma Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 59. Spectrum Pharmaceuticals Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 60. Pfizer Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 61. Sigma-Tau Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 62. Takeda Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 63. Genzyme Corporatio Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 64. GSK Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 65. Amgen Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 66. EUSA Pharma Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 67. ARIAD Pharmaceuticals Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 68. Talon Therapeutics Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 69. Enzon, Inc. Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 70. Nova Laboratories Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 71. Bristol-Myers Squibb Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 72. Silvergate Pharmaceuticals Revenue Growth Rate in Acute Lymphoblastic Leukemia Therapeutics Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

---